ICD-10 · PDGM grouping
C54 Malignant neoplasm of corpus uteri
All 6 codes in the C54 family, with the PDGM clinical group, comorbidity subgroup and primary-position rule CMS assigns, read from the CMS grouper crosswalk v07.2.26 and the CDC FY2027 code file.
Codes in family
6
Can lead a claim
6
Cannot lead a claim
0
What CMS assigns to C54
All 6 codes group to MMTA - Infectious Disease, Neoplasms, and Blood-Forming Diseases. 4 of the 6 count toward the Malignant Neoplasm of Female Genital Organs and Prostate comorbidity subgroup; 2 are assigned none. Every code can lead a claim.
- Malignant Neoplasm of Female Genital Organs and Prostate
Every code in C54
Descriptions are CDC’s FY2027 wording; where CMS’s grouper abbreviates one, its form is shown beneath.
| Code | Description | Primary position | Clinical group | Comorbidity subgroup |
|---|---|---|---|---|
| C54.0 | Malignant neoplasm of isthmus uteri | Can lead a claim | K | None |
| C54.1 | Malignant neoplasm of endometrium | Can lead a claim | K | Malignant Neoplasm of Female Genital Organs and Prostate |
| C54.2 | Malignant neoplasm of myometrium | Can lead a claim | K | Malignant Neoplasm of Female Genital Organs and Prostate |
| C54.3 | Malignant neoplasm of fundus uteri | Can lead a claim | K | Malignant Neoplasm of Female Genital Organs and Prostate |
| C54.8 | Malignant neoplasm of overlapping sites of corpus uteri | Can lead a claim | K | None |
| C54.9 | Malignant neoplasm of corpus uteri, unspecified | Can lead a claim | K | Malignant Neoplasm of Female Genital Organs and Prostate |
Sources: CMS HH PPS Grouper Software v07.2.26, effective 2026-10-01, for the clinical group, comorbidity subgroup, code-first conventions and primary-position flags; CDC NCHS ICD-10-CM FY2027 code descriptions for the family title and code wording. This is the crosswalk Medicare runs a claim through. Grouping also depends on admission source, timing, the OASIS functional items and the rest of the diagnosis list.
The monthly home health regs digest
What CMS changed, what's due next, and what to do about it — one email a month, no fluff. Read the first issue